Study guide

10.2 Cellular Therapies including CAR-T

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

10.2 Cellular Therapies including CAR-T

Key Takeaways Explain This Topic AI

Autologous CD19 CAR-T for relapsed/refractory B-ALL (and some lymphomas) infuses living T cells that carry an artificial CD19 receptor; it is not HSCT and is not a single commercial brand.

The sequence is leukapheresis, manufacturing, lymphodepleting fludarabine plus cyclophosphamide, infusion, then in vivo expansion.

CRS is IL-6-driven fever, hypoxia, and hypotension after expansion; first-line nursing is tocilizumab (an IL-6 receptor antagonist) plus supportive care and early ICU transfer for refractory shock or high oxygen need.

ICANS presents with delirium, aphasia, seizures, and possible cerebral edema; use ICE-style neurologic checks, corticosteroids, and protocol seizure prophylaxis.

Prolonged B-cell aplasia is on-target toxicity and is managed with IVIG; infection, cytopenias, and HLH-like inflammation remain after-care risks.

Last updated: August 2026

Cellular therapy infuses living immune cells that have been collected, modified, or selected to attack cancer. CPHON TCO III.B.5 is not the hematopoietic stem cell transplant (HSCT) section (III.B.7). Autologous CD19 chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory B-ALL —and some B-cell lymphomas—is the high-yield pediatric product. Use the generic name CD19 CAR-T . Do not treat one commercial brand as the only 2026 ONCC product; several licensed and protocol products share the CD19 target, the lymphodepletion backbone, and the same two toxicities: cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) .

This is not transplant

HSCT replaces marrow with donor or autologous stem cells after high-dose conditioning; engraftment reconstitutes all blood lines, graft-versus-host disease is an allogeneic-donor-cell problem, and the product is hematopoietic progenitors. CAR-T is a targeted immune-cell drug. The child keeps native marrow (already damaged by prior therapy) and receives T cells that carry an artificial receptor against CD19 . Autologous CD19 CAR-T does not cause classic graft-versus-host disease from an allogeneic graft. It does kill healthy CD19-positive B cells, which causes prolonged B-cell aplasia . Mixing the two on a consent conversation is how families pack for "another transplant" and miss CRS teaching.

Other pediatric cellular products exist (virus-specific T cells, investigational solid-tumor CARs). CPHON items still orbit autologous CD19 CAR-T for B-ALL . A 9-year-old in second marrow relapse after intensive chemotherapy is the classic candidate picture; a newly diagnosed standard-risk preschooler on day 4 of induction is not.

The sequence: apheresis → lymphodepletion → infusion → expansion

Leukapheresis collects T cells through a large-bore or apheresis catheter. Collection-day nursing is counts, ionized calcium (citrate binding causes perioral tingling and tetany), and line thrombosis or bleeding. The product ships to a manufacturing lab. The child may receive bridging chemotherapy to hold the leukemia while cells are grown; bridging is not the CAR-T itself. Manufacturing turnaround is days to weeks—teach the concept, not an invented ONCC-mandatory day count.

Lymphodepleting chemotherapy , classically fludarabine plus cyclophosphamide , makes immunologic space and homeostatic cytokines so the CAR-T cells can expand. Expect cytopenias, infection risk, and hemorrhagic-cystitis precautions with cyclophosphamide (hydration; mesna if the protocol uses it). This chemo is a means to expansion, not the curative intent by itself.

Infusion is a blood-product-style cell bag: two-identifier check, vital signs, emergency drugs at the bedside. Premedicate per protocol (commonly acetaminophen and an antihistamine). Avoid routine high-dose corticosteroids at infusion that might blunt CAR-T function unless a protocol exception exists—this is the opposite instinct from checkpoint-inhibitor irAE treatment in the last section. Do not filter away the cells with an inappropriate filter. Stay in the room.

Expansion over the following days is when CAR-T cells proliferate, kill CD19-positive blasts, and release cytokines. CRS and ICANS declare themselves here, often in the first one to two weeks, with product-specific windows. Fever is the opening move, not a reason to send the child to the playroom unmonitored. A 9-year-old who looks well on the evening of infusion and spikes 39.2°C on day 4 is in the expansion window until proven otherwise.

CRS: mechanism and first-line nursing

Activated CAR-T cells and macrophages pour out interleukin-6 (IL-6) and other cytokines. Clinically, CRS is a spectrum. Fever is the grade-defining start in most systems. Hypotension and capillary leak follow. Hypoxia and pulmonary edema mark higher grades. Grading language—fever alone versus hypotension that responds to fluids versus hypoxia or shock needing intensive care—is the exam concept. Do not memorize one society's exact numeric table as if ONCC published it. The dedicated cytokine-release-syndrome emergency section later in this guide owns staging algorithms. This section's job is mechanism and first-line nursing.

Notify the cellular-therapy team early . CRS can climb in hours.

Supportive care: antipyretics as allowed, oxygen, fluid boluses with caution for leak, cultures, and broad-spectrum antibiotics for febrile neutropenia per protocol because infection and CRS coexist .

Tocilizumab , an IL-6 receptor antagonist , is the targeted first-line drug for CRS that meets protocol treatment criteria (typically hypotension, hypoxia, or a rapid grade rise—not every isolated low-grade fever). Give it as ordered; do not wait for a code.

Intensive-care unit (ICU) transfer for refractory hypotension, high oxygen need, or rapid evolution. Vasopressors and ventilatory support are ICU tools; the floor nurse's job is not to "tough out" high-grade CRS in a regular room.

Steroids are used for severe or refractory CRS and for ICANS. For many CRS protocols they come after tocilizumab because they can dampen CAR-T activity. Follow the product protocol, not a general oncology steroid habit.

ICANS: the brain after the fever

ICANS is neurotoxicity from immune-effector cells: delirium, tremor, aphasia (cannot name objects or write), depressed consciousness, seizures , and, at the extreme, cerebral edema . It may follow CRS or appear on its own. ICE-style neurologic checks (Immune Effector Cell–Associated Encephalopathy: orientation, naming, following commands, writing, attention) run on a clock, not only when a parent says the child "seems off." Adapt the tasks for younger children (follow a command, name a familiar toy, track, speak). A 12-year-old who cannot write her name the morning after fever is ICANS until proven otherwise.

Nursing: serial ICE-style exams and a low threshold to call; seizure prophylaxis when the protocol requires it (often levetiracetam in higher-risk windows); corticosteroids as first-line treatment for significant ICANS on most product protocols; airway protection and head-of-bed positioning as ordered; treat cerebral edema as a neuro-emergency, not as "chemo fog." Do not assume every headache is ICANS; do not assume every aphasia is anxiety. Tocilizumab treats CRS; it is not the automatic first drug for isolated ICANS without CRS.

After the cells: B-cell aplasia, infection, cytopenias, HLH-like illness

Because CD19 CAR-T also kill normal B cells, hypogammaglobulinemia and prolonged B-cell aplasia are expected on-target toxicities. Intravenous immunoglobulin (IVIG) replacement is used when IgG is low or infections accumulate. Teach families that IVIG is not optional "extra immunity" and that live vaccines wait until B-cell recovery and team clearance.

Cytopenias can last weeks: transfusion support, growth factors per protocol, and bleeding precautions. Infection (bacterial, viral, fungal) is the leading late killer after the CRS window. Hemophagocytic lymphohistiocytosis (HLH)–like or macrophage-activation pictures (ferritin surge, cytopenias, organ failure) overlap with severe CRS—notify; do not invent a home ferritin cutoff as ONCC fact.

A 9-year-old with second-relapse B-ALL who receives CD19 CAR-T, spikes fever on day 4, and then cannot name a watch is the CPHON picture: fever is CRS until dual-worked, tocilizumab is the IL-6 move, ICE-style checks catch ICANS, steroids treat the brain, and IVIG waits in the after-care folder because B cells are gone.

  • Phase What happens Nursing watch
  • Apheresis Collect autologous T cells Catheter, citrate/calcium, counts
  • Lymphodepletion Fludarabine plus cyclophosphamide Cytopenias, infection, cystitis precautions
  • Infusion CD19 CAR-T bag Identifier check, no inappropriate filter, bedside emergency drugs
  • Expansion Cells proliferate CRS: fever, hypoxia, hypotension → tocilizumab, ICU
  • Neuro window ICANS ICE-style checks, steroids, seizure prophylaxis
  • Recovery B-cell aplasia IVIG, infection, cytopenias, HLH-like labs

Loading diagram... Autologous CD19 CAR-T sequence and first-line toxicities